Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Novartis Sverige Participations AB, a prominent subsidiary of the global healthcare leader Novartis AG, is headquartered in Sweden (SE) and plays a vital role in the pharmaceutical industry. Established in the early 2000s, the company focuses on innovative medicines and advanced therapies, particularly in areas such as oncology, cardiology, and immunology.
With a commitment to research and development, Novartis Sverige has achieved significant milestones, including the introduction of groundbreaking treatments that address unmet medical needs. The company is renowned for its unique portfolio of patented drugs and biologics, which are designed to improve patient outcomes and enhance quality of life.
As a key player in the Swedish healthcare market, Novartis Sverige Participations AB is recognised for its contributions to medical science and its dedication to sustainable healthcare solutions, solidifying its position as a leader in the pharmaceutical sector.
+71 vs industry average
Novartis Sverige Participations AB’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Real Estate Services has above-average carbon intensity
The Real Estate Services industry has reduced its overall emissions by 17% since 2018
No reported emissions data is available for Novartis Sverige Participations AB yet.
Novartis Sverige Participations AB currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Novartis AG, which cascades its climate commitments and initiatives down to its subsidiaries.
Novartis AG has established various climate initiatives, including targets set through the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are relevant to Novartis Sverige Participations AB. These initiatives aim to significantly reduce carbon emissions across their operations, although specific reduction targets for Novartis Sverige Participations AB have not been detailed.
As a part of its commitment to sustainability, Novartis AG has pledged to enhance its climate strategies, which are expected to influence the operational practices of its subsidiaries, including Novartis Sverige Participations AB. However, without specific emissions data or reduction targets available for the subsidiary, a comprehensive assessment of its carbon footprint and climate commitments cannot be provided at this time.
No climate goals have been disclosed for Novartis Sverige Participations AB yet.
No scope 3 category breakdown has been disclosed yet.


No peer comparison is available for Novartis Sverige Participations AB yet.
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more